Patents Assigned to Heifei Zhongke Longwood Biotechnology Co., Ltd.
  • Human FGF21 mutant with improved effectiveness and stability and pharmaceutical composition thereof
    Patent number: 11746134
    Abstract: The present disclosure relates to a human FGF21 mutant with improved effectiveness and stability, preparation method and pharmaceutical composition comprising the mutant, and a use thereof, and specifically relates to a human fibroblast growth factor 21 (FGF21) mutant, a gene encoding the same, and a method for preparing the mutant and a method of using the mutant for treating type 2 diabetes, obesity, dyslipidemia, or metabolic disorders.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 5, 2023
    Assignee: Heifei Zhongke Longwood Biotechnology Co., Ltd.
    Inventors: Junfeng Wang, Hongxin Zhao, Lei Zhu